GRAIL, Inc. (GRAL) stock intrinsic value fair value estimate & owner earnings analysis

GRAIL sells Galleri, a blood test that looks for a shared cancer signal from a single sample; in its studies it identified the signal across more than 50 types of cancer. Almost all of its revenue (about $138.6M of $147.2M in 2025) is from screening; the rest is development services for partners. Revenue has grown each year, from $93.1M in 2023 to $125.6M in 2024 and $147.2M in 2025, and the first half of 2026 was $85.5M against $67.4M a year earlier (about 27% higher). But the company loses a great deal of cash. Cash from operations was negative $595.8M in 2023, $577.2M in 2024 and $299.0M in 2025, and $167.7M was used in the first half of 2026, about the same as the $172.0M in the first half of 2025. How we measure it: owner earnings are operating cash flow, less the swing from working capital, less stock compensation (a real cost paid in shares), less the part of capital spending needed just to stay in business. On that basis owner earnings were about negative $711M in 2023, negative $642M in 2024 and negative $370M in 2025, or about negative $22.91, negative $20.13 and negative $10.06 per share. As a cross-check, net loss plus non-cash charges (amortization, depreciation, stock pay, deferred taxes, impairments) less maintenance capital spending reproduces the reported operating cash flow adjusted for working capital within rounding, so no line was missed. The large intangible amortization (about $138M a year) and the goodwill write-downs ($718M in 2023, $1.42B in 2024, $28M in 2025) are non-cash and are not deducted again; they reflect the value booked when Illumina acquired GRAIL being written down. We used 2025 as the reference year because it follows the restructuring that cut costs; the older years describe a much larger cost base. Owner earnings improved by about $272M in 2025. We assume no further improvement in the near term, because the first half of 2026 burn was flat with the prior year, which is below the trailing rate of improvement. What we count as value: at June 30, 2026 the company held $55.6M in cash plus about $859.5M in investment securities, roughly $915M, or about $21 per share on about 43.1 million diluted shares. We do not treat that cash as surplus. The business consumes it at roughly $335M a year at the current rate (double the $167.7M used in the first half of 2026), so it would last about two and three-quarter years. We found nothing in the filings that guarantees the business will earn a positive return. Galleri is not FDA approved; the company has submitted an approval application to the FDA, and the pending review is not something we count. The three-year NHS-Galleri trial did not meet its main goal of a statistically significant reduction in combined stage 3 and 4 cancers, although the company reports a reduction of more than 20% in stage 4 cancers; the company planned to share final results in mid-2026. A decision by the UK health service on whether to use the test has not been made. Growth in test sales counts for nothing in our cases: it has not yet produced a profit and depends on adoption and coverage decisions that have not happened. Bear case, $0 per share: spending continues near today's level, the cash is consumed, and any further money must be raised on terms that leave existing shareholders with little. The filing also flags that any funds Illumina can claw back under the spin-off terms would reduce cash. Base case, about $1.55 per share: spending stays near $335M a year for about two and a half years, after which roughly $77M (about $1.80 per share) would be left; discounted at 6% that is about $1.55. Bull case, about $5 per share: spending falls the way it did in 2025, to roughly $300M, $200M and $150M over three years, leaving about $265M, or about $6.10 per share, which is about $5 discounted. In every case the business itself is credited with no earning power because none has been shown. Not counted: an agreement signed October 2025 for Samsung entities to purchase 1,570,308 shares at $70.05 each and to partner on Galleri in South Korea; it was subject to closing conditions and we could not confirm it closed. If it did, cash and value per share would be higher by roughly $110M in total. Also not counted: any FDA approval. What would make this wrong: FDA approval with broad insurance coverage, or a national health-service purchase, could turn the losses into profits. The margin-of-safety price of $0.75 reflects a business whose value at present rests only on cash that is being spent.